Aurinia pharmaceuticals inc stock

Is Aurinia Pharmaceuticals Inc (AUPH) Stock a Good ... Mar 04, 2020 · Aurinia Pharmaceuticals Inc stock is higher by 183.87% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives AUPH stock a score of 73 out of a possible 100. That rank is … AUP Stock Price, Forecast & News (Aurinia Pharmaceuticals)

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious AUPH: Dividend Date & History for Aurinia Pharmaceuticals Inc Aurinia Pharmaceuticals Inc (AUPH) Stock Dividend Data. AUPH Stock Dividend Data. Dividend Yield Dividend Yield. Dividend yield is the relation between a stock’s annual dividend payout and its current stock price. Click here to learn more. 0.00% healthcare Average 0.01% ANNUALIZED Aurinia Pharmaceuticals Stock Quote. AUPH - Stock Price ... Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). AUPH.O - Aurinia Pharmaceuticals Inc News | Reuters

AUPH | Aurinia Pharmaceuticals Inc. Stock Price & News - WSJ

AUPH Stock | AURINIA PHARMACEUTICALS Stock Price Today ... Apr 03, 2020 · Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug … AUPH | Aurinia Pharmaceuticals Inc. Stock Price & News - WSJ View the latest Aurinia Pharmaceuticals Inc. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) stock Plunged ...

"Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal

AUP:Toronto Stock Quote - Aurinia Pharmaceuticals Inc ... Stock analysis for Aurinia Pharmaceuticals Inc (AUP:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Company Information :: Aurinia Pharmaceuticals Inc. (AUPH) Company Information Company Profile Aurinia is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to change the treatment paradigm for patients impacted by rare autoimmune and inflammatory conditions. Contact Us :: Aurinia Pharmaceuticals Inc. (AUPH)

Aurinia Pharmaceuticals Inc. (AUPH)

Find the latest Aurinia Pharmaceuticals Inc (AUPH) stock quote, history, news and other vital information to help you with your stock trading and investing.

Stock Comparison: Compare Aurinia Pharmaceuticals Inc ...

Aurinia Pharmaceuticals (AUPH) Stock Tumbles on Lupus Drug Trial Deaths · By Rachel Aldrich. Aug 15, 2016 11:35 AM EDT. Loading… Load More. TheStreet. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has 6 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange  Historical daily share price chart and data for Aurinia Pharmaceuticals Inc since 2020 adjusted for splits. The latest closing stock price for Aurinia 

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need. AUPH - Stock quote for Aurinia Pharmaceuticals Inc. - MSN ... View the latest AUPH stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of Aurinia Pharmaceuticals Inc.. Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH ...